Mohr Marketing Deploys AI WebTracker® to Target High-Value NAION and Verified Gastroparesis Claims Amid New 2026 Medical Evidence

As GLP-1 litigation enters a critical juncture, Mohr Marketing, LLC has announced the deployment of enhanced precision-targeting technologies to assist law firms in securing high-value claims. With federal case counts nearing 3,200 actions in MDL 3094 and the formalization of MDL 3163 (focused exclusively on vision loss), the industry is shifting from volume-based intake to medically-vetted, high-settlement potential cases.

The New Evidence: The NAION “Eye Stroke” Risk

A landmark study published in JAMA Ophthalmology in February 2026 has provided fresh momentum for plaintiffs. The data reveals that semaglutide (Ozempic®/Wegovy®) initiators face a twofold higher risk of incident NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) compared to those on other diabetes medications.

“The science is settling in favor of the plaintiffs,” stated Ed Mohr, President of Mohr Marketing. “With vision loss cases estimated to carry significantly higher settlement values than general gastrointestinal claims, we have optimized our AI WebTracker® to identify individuals specifically diagnosed with NAION or ‘eye stroke’ symptoms immediately following Ozempic use.”

The “Scintigraphy Standard” for Gastroparesis

In recent court orders from the Eastern District of Pennsylvania, Judge Karen Marston has signaled a tightening of diagnostic requirements for stomach paralysis claims. To survive defense motions, the court now leans toward objective medical testing—specifically Gastric Emptying Studies (Scintigraphy) or Breath Tests.

To combat the risk of “junk leads,” Mohr Marketing’s proprietary Scammer Scrub™ technology now includes automated filters that prioritize claimants with:

• Documented hospitalizations (24+ hours).
• Confirmed diagnostic imaging results.
• Verified drug brand and duration of use.

Technological Competitive Advantages

Mohr Marketing provides a comprehensive “Compliance Shield” through its Joint Advertising Compliance Program, allowing law firms to scale dockets without the ethical risks of traditional lead-buying:

• AI WebTracker®: Monitors real-time behavior to find claimants searching for specific specialists (Ophthalmologists/Gastroenterologists) rather than generic “weight loss” terms.
• Scammer Scrub™: Eliminates professional plaintiffs and bot-generated data, ensuring a higher signed-case-to-lead ratio.
• Bilingual Intake: Every lead is screened 24/7 by trained specialists who verify the clinical criteria before the file is delivered.

A Critical Window for Legal Intake

As bellwether trials approach later in 2026, the cost of acquisition is expected to spike. Firms that secure their dockets now—focusing on the 4-fold increased risk in diabetic patients and 7-fold risk in obese patients for NAION—will be best positioned for upcoming settlement negotiations.

“We aren’t just sending leads; we are delivering trial-ready dossiers,” stated Mohr. “By integrating the latest February 2026 medical data into our AI algorithms, we ensure our partners are investing in the most legally viable cases in the GLP-1 space.”

About Mohr Marketing, LLC

Mohr Marketing, LLC is a premier legal marketing agency specializing in high-value lead generation for Mass Torts, Personal Injury, and specialized medical litigation. Utilizing proprietary technologies like AI WebTracker® and Scammer Scrub™, Mohr Marketing connects top-tier law firms with medically-vetted claimants. All campaigns are managed under a Joint Advertising Compliance Program to ensure the highest ethical and legal standards.

Media Contact:
Ed Mohr
Mohr Marketing, LLC
866-695-9058
**@******tg.com

Summary

Article Name

The GLP-1 Litigation Landscape has Shifted: Is Your Docket Trial-Ready for 2026?

Description

Mohr Marketing Deploys AI WebTracker® to Target High-Value NAION and Verified Gastroparesis Claims Amid New 2026 Medical Evidence.

Author

Mohr Marketing Team

Publisher Name

Mohr Marketing, LLC

Publisher Logo